I started out by setting up the deep-sequencing core at Mount Sinai, NY and enjoyed the science so much that I continued on to get a Ph.D. During my Ph.D I developed several sequencing-related technologies (patents pending). I want to harness these and other sequencing-based technologies to enable more precise delivery of diagnoses and drugs through the development of novel biomarkers
I had worked in a few labs and did my degree, but I feel I never truly started until Anitha and Ravi mentored me. With their help, I did my final year thesis on mitochondrial DNA sequencing and became immersed in the world of genomics that is now an integral part of my scientific journey. Girihlet is a special place that challenges you to do a different kind of science, a pragmatic science. There's a great feeling you get when you really get to apply your knowledge, and Girihlet is the place to do it.
Girihlet has given me the platform to be a part of the one of the most significant technological advances, deep sequencing, in the field of biology. Coming from a microbiology background I would like to understand the bigger picture by examining the smallest details in the tiniest organisms with these technologies in the long run.
Advances in sequencing have not translated to profound changes in the practise of medicine. We aim to harness these advances (resulting from the efforts of us and many others) to develop novel biomarkers and enable them to be used inexpensively, affording greater diagnostic accuracy.
Former HIV molecular biologist, eager and excited to apply his skills in the burgeoning field of genomics and sequencing.
Having worked in academic settings for many years, in basic sciences and in molecular biology, I was attracted by the innovative ideas behind the founding premise of the company and its culture. It is exciting to be working in the forefront of biotechnology and to help Girihlet reach its potential.
I am an interdisciplinary research scientist. I completed my PhD in India and my postdoctoral research in the USA. I was overjoyed and jumped at the opportunity to work at Girihlet, in the field of genomics to broaden my horizons and continue my passion for research. There is a huge potential for genomics in precision medicine, diagnostics, R&D and applications in every rank of the systematic taxonomic classification system. Girihlet will provide me a platform to make valuable contributions and leave behind a lasting legacy.
I am currently an undergrad studying Biology at The City College of New York. My inspiration behind joining Girihlet was to challenge myself through exposure to lab work and to acquire a clear grasp of the field of genomics and sequencing. It has been a great opportunity for me to build and enhance my skills in laboratory work.
I am currently an undergraduate studying biochemistry at UC Berkeley and am very excited to join Girihlet on their quest to make sequencing technology more available for use in medicine. Working with them has allowed me to meet people passionate about what they do, and it inspires me to improve my skills and to creatively apply the knowledge I have.
Dr Brian Naughton was Founding Scientist at 23andMe from 2006 until 2014. In this role, Dr Naughton drew on his experience in bioinformatics, statistics and genetics to analyze data, develop algorithms and translate scientific research to drive the world's first Personal Genome Service. While at 23andMe, Dr Naughton worked on the design and development of the company's custom genotyping arrays and other sequencing technologies, as well as the development of the company's web-based tools related to disease risk estimation, pharmacogenomics, recessive disease testing, ancestry, and genealogy. Dr Naughton was PI for 23andMe's SBIR grant on DNA sequencing quality metrics and launched the company's pilot exome sequencing projects. Dr Naughton earned a PhD from the Biomedical Informatics program at Stanford University and a BA in Human Genetics from Trinity College, Dublin.
Mat Falkowski is a serial entrepreneur who has been at 5 biotech start-ups over the past 15 years. Recently he was a founder at Invitea, which went IPO in Feb 2015 and is now processing over 70,000 clinical patient samples per year for a range of genetic tests. Over the past 15 years he has been actively involved in developing lab tests, running service labs, product rollout, marketing, grant writing, and fund raising.